Glucagon-like peptide-1 (GLP-1) analogues aid weight loss that improves obesity-associated adipose tissue (AT) dysfunction. GLP-1 treatment may however also directly influence AT that expresses the GLP-1 receptor (GLP-1R). The present study aimed to assess the impact of GLP-1 analogue treatment on subcutaneous AT (SCAT) inflammatory and fibrotic responses, compared with weight loss by calorie reduction (control). Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8). Assessments included clinical characteristics and repeated subcutaneous abdominal AT biopsies. Liraglutide resulted in weight loss in most participants (−3.12±1.72 kg, P=0.007) and significant reduction in visceral AT (VAT). It was more effective in lowering fasting glucose, in comparison with weight loss by dieting. However, tumour necrosis factor-α (TNFA) AT-expression (P=0.0005), macrophage chemoattractant protein-1 (MCP-1) expression (P=0.027) and its serum levels (P=0.048) increased with Liraglutide, suggestive of an inflammatory response unlike in the diet arm in which a trend of lower cluster of differentiation 14 (CD14) expression (P=0.09) was found. Liraglutide treatment also increased expression of factors involved in extracellular matrix (ECM) deposition, transforming growth factor-β (TGFB) and collagen type 1 alpha 1 chain (COL1A1) (TGFB1: before 0.73±0.09 arbitrary units (AU), after 1.00±0.13 AU, P=0.006; COL1A1: 0.84±0.09 AU compared with 1.49±0.26 AU, P=0.026). Liraglutide thus appears to induce an inflammatory response in AT and influences ECM remodelling. Despite its superior effect on glycaemia, Liraglutide does not improve obesity-associated AT dysfunction in subcutaneous tissue. It is yet unclear whether this limits AT storage capacity for lipids. This may be of importance in patients being re-exposed to positive energy balance such as post GLP-1 discontinuation.
Skip Nav Destination
Article navigation
March 2017
-
Cover Image
Cover Image
Phase contrast microscopy showing primary human mesangial cells in culture. Quantification of cell area showed that exposure of mesangial cells to the pro-fibrotic growth factor (TGF-β1) induced morphological cell expansion and hypertrophy, which was reversed following the overexpression of miR-378. Interestingly, transfection of a miR-378 inhibitor induced the expansion of mesangial cells, highlighting the regulatory role of miR-378 in mesangial hypertrophy. Please see the article by Wang et al. (pages 411-423).
Research Article|
February 15 2017
GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction Available to Purchase
Emilie Pastel;
Emilie Pastel
1Diabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Laura J. McCulloch;
Laura J. McCulloch
1Diabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Rebecca Ward;
Rebecca Ward
1Diabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Shivam Joshi;
Shivam Joshi
1Diabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Kim M. Gooding;
Kim M. Gooding
2Diabetes and Vascular Medicine, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Angela C. Shore;
Angela C. Shore
2Diabetes and Vascular Medicine, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Search for other works by this author on:
Katarina Kos
1Diabetes and Obesity Research Group, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, U.K.
Correspondence: Katarina Kos ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
October 21 2016
Revision Received:
December 20 2016
Accepted:
December 22 2016
Accepted Manuscript online:
January 03 2017
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2017 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2017
Clin Sci (Lond) (2017) 131 (5): 343–353.
Article history
Received:
October 21 2016
Revision Received:
December 20 2016
Accepted:
December 22 2016
Accepted Manuscript online:
January 03 2017
Citation
Emilie Pastel, Laura J. McCulloch, Rebecca Ward, Shivam Joshi, Kim M. Gooding, Angela C. Shore, Katarina Kos; GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond) 1 March 2017; 131 (5): 343–353. doi: https://doi.org/10.1042/CS20160803
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |